USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/19243
Title: Secondary neuroimaging changes following treatment with Vigabatrin (clinical case)
Authors: Calcîi, Cornelia
Sprincean, Mariana
Feghiu, Ludmila
Cuzneț, Ludmila
Groppa, Stanislav
Hadjiu, Svetlana
Keywords: West sindrom;epilepsy;Vigabatrin
Issue Date: 2021
Publisher: Universitatea de Stat de Medicină și Farmacie ”Nicolae Testemițanu” din Republica Moldova
Citation: CALCÎI, Cornelia, SPRINCEAN, Mariana, FEGHIU, Ludmila, et al. Secondary neuroimaging changes following treatment with Vigabatrin (clinical case): [poster]. In: Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 20-22 octombrie 2021: culegere de postere. 2021, p. 148.
Abstract: Introduction. Some studies show an association between the occurrence of neuroimaging changes (MRI) and Vigabatrin treatment in West syndrome in children, all changes being reversible and dose dependent. Purpose. Evaluation of neuroimaging peculiarities secondary to Vigabatrin treatment based on a clinical case. Material and methods. We evaluated the case of a 1-year-old 7-month-old boy diagnosed with West syndrome who was hospitalized in 2019 in the Hospital of Mother and Child Health Care where he received treatment with Vigabatrin. At the age of 6 months the child presented the clinical picture of infantile spasms and delay in neuropsychic development, being diagnosed with West syndrome. The first neuroimaging investigation MRI was performed at the age of 8 months, and the repeated one after 6 months of treatment with Vigabatrin Results. The child performed the first brain MRI, where periventricular cysts, a minimized volume of cerebral white matter with periventricular gliosis, with reduction of hippocampal volume and enlargement of the ventricular and cisternal system were described. After the initiation of Vigabatrin treatment, the seizures stopped. The same changes were described on the repeated MRI examination (after 6 months), but small gliotic lesions appeared in the brainstem and tegmetum, which were not previously described. Conclusions. Brain MRI changes may be seen in children with epilepsy treated with Vigabatrin. These may include increased signal in T2 and transient changes in the brainstem, usually being dose dependent and disappearing after discontinuation of treatment.
metadata.dc.relation.ispartof: Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 20-22 octombrie 2021
URI: http://repository.usmf.md/handle/20.500.12710/19243
Appears in Collections:Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 20-22 octombrie 2021: Culegere de postere

Files in This Item:
File Description SizeFormat 
SECONDARY_NEUROIMAGING_CHANGES_FOLLOWING_TREATMENT_WITH_VIGABATRIN_CLINICAL_CASE.pdf472.82 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback